AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Tatglipt-M Tablet ER

Prescription Icon
Prescription Required

Marketer

Pariza Healthcare

Salt Composition

Metformin (500mg) + Teneligliptin (20mg)

Overview Tatglipt-M Tablet ER

Metformin/Linagliptin Extended-Release tablets manage elevated blood glucose in type 2 diabetes patients by combining two active ingredients. This dual action helps prevent serious diabetic complications like vision impairment and kidney disease, and may lessen the risk of stroke or heart attack. The medication may be prescribed alone or in conjunction with other antidiabetic agents. Optimal efficacy is achieved through adherence to a healthy diet and regular physical activity. Dosage is individualized based on your health status, blood sugar readings, and concurrent medications. Consuming this medication with food minimizes gastrointestinal upset. Consistent daily dosing at the same time maximizes benefits; discontinuation should only occur under physician guidance. It effectively controls blood sugar, mitigating future complications. Continued adherence to your doctor's dietary and exercise plan is crucial. Lifestyle choices are integral to managing diabetes. Common side effects include nausea, diarrhea, vomiting, stomach discomfort, and headache. Hypoglycemia is a potential side effect, especially when used with insulin or sulfonylureas; learn its symptoms and treatment. This medication isn't suitable for everyone. Prior to initiating treatment, inform your physician of any history of liver, kidney, or heart disease, pancreatic issues, or significant alcohol consumption. Pregnant or nursing individuals should consult their doctor. Interactions with other medications are possible; disclose all medications to your doctor to ensure safety. Alcohol should be limited due to its hypoglycemic effect. Your doctor will monitor your kidney function and blood glucose levels throughout treatment.

Uses of Tatglipt-M Tablet ER

Managing type 2 diabetes

Major Benefits of Tatglipt-M Tablet ER:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Tatglipt-M Extended-Release Tablet with a meal.

Common Side effects of Tatglipt-M Tablet ER:

  • Nausea
  • Vomiting
  • Headache
  • Hypoglycemia (low blood glucose level)
  • Diarrhea

How to use Tatglipt-M Tablet ER:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment period. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. Tatglipt-M Extended-Release Tablet should be administered with a meal.

How Tatglipt-M Tablet ER works:

Extended-release Tatglipt-M tablets contain a dual antidiabetic medication formulation.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Tatglipt-M Tablet ER and alcohol is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The extended-release Tatglipt-M tablet might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Patient consultation with their doctor is advised.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Tatglipt-M tablets are likely unsafe for breastfeeding mothers. Available human data indicate potential transfer of the medication into breast milk, posing a risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

The effect of Tatglipt-M Tablet ER on driving ability is undetermined. Refrain from driving if experiencing symptoms impairing concentration or reaction time.

KidneyKidneyCAUTION

Patients with impaired kidney function should use Tatglipt-M ER tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates the use of Tatglipt-M ER tablets. Physician consultation is recommended. Regular kidney function monitoring is advised during treatment.

LiverLiverUNSAFE

Extended-release Tatglipt-M tablets are contraindicated for individuals with hepatic impairment and should be omitted. Physician consultation is recommended.

What if you forget to take Tatglipt-M Tablet ER :

Should you forget a dose of Tatglipt-M Tablet ER, take it immediately if you remember. Otherwise, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Never take a double dose.

Facts to Know About Tatglipt-M Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Tatglipt-M Tablet ER

Using Tatglipt-M Tablet ER as directed by your doctor is safe. However, even with correct dosage, side effects such as nausea, diarrhea, vomiting, stomach upset, headache, nasal congestion, sore throat, respiratory infection, and hypoglycemia (low blood sugar) may occur. Hypoglycemia is more likely if you're also taking insulin or sulfonylurea. Report any persistent issues to your doctor.
Tatglipt-M ER tablets rarely cause hypoglycemia by themselves, but low blood sugar can occur if you don't eat enough while taking them. Symptoms include nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, and shakiness, especially if you skip meals, drink alcohol, overexert yourself, or take other diabetes medication. Regular blood sugar monitoring is essential. Always carry a fast-acting sugar source, such as glucose tablets, honey, or fruit juice.
Nausea and vomiting are possible side effects of Tatglipt-M Tablet ER. If vomiting occurs, sip small amounts of water or other fluids frequently. Consult your doctor if vomiting continues or you experience dehydration symptoms such as dark, strong-smelling urine and infrequent urination. Never take other medications without your doctor's approval.
Patients with known allergies to Tatglipt-M Tablet ER components or excipients should not use this medication. It is also contraindicated in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Tatglipt-M Tablet ER can cause lactic acidosis (MALA), a rare but serious complication resulting from elevated blood lactic acid levels. This risk is higher in patients with kidney disease, the elderly, or those who consume excessive alcohol, hence its avoidance in these groups. Symptoms may include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Tatglipt-M Tablet ER and seek immediate medical attention.
Prolonged use of Tatglipt-M Tablet ER can lead to vitamin B12 deficiency by impairing its absorption in the stomach. This deficiency may result in anemia, nerve damage (potentially causing tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and balance problems), necessitating medical attention. If you experience such symptoms, consult your doctor; they may recommend vitamin B12 level monitoring and supplementation.
Store this medication in its original, tightly closed container, following the instructions on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Tatglipt-M Tablet ER
74
MRP 90
17% off